Stock comparison
BrainsWay
Haemonetics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BWAY
BrainsWay
Market cap
$592.27M
Sector
Healthcare
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BWAY | HAE | Winner |
|---|---|---|---|
| Warren Buffett | 43D | 70B | HAE |
| Benjamin Graham | 70D | 85A | HAE |
| Philip Fisher | 57C | 60C | HAE |
| Peter Lynch | 52C | 54C | HAE |
| Joel Greenblatt | 46D | 31F | BWAY |
| Charlie Munger | 41D | 54D | HAE |
| Terry Smith | 52D | 55D | HAE |
Side-by-side metrics
| Metric | BWAY | HAE |
|---|---|---|
| Market cap | $592.27M | $2.98B |
| P/E (TTM) | 75.0x | 24.8x |
| EV/EBIT | 123.9x | 14.1x |
| ROIC (TTM) | 5.05% | 8.37% |
| Gross margin | 75.42% | 55.74% |
| Net margin | 13.5% | 7.29% |
| Revenue CAGR 5y | 15.42% | 7.65% |
| EPS CAGR 5y | - | 24.62% |
| Debt / Equity | 0.1x | 1.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BWAY leads on
- Debt / Equity0.1xvs 1.5x+94%
- Revenue CAGR 5y15.42%vs 7.65%+50%
- Net margin13.5%vs 7.29%+46%
- Gross margin75.42%vs 55.74%+26%
HAE leads on
- EV/EBIT14.1xvs 123.9x+89%
- Market cap$2.98Bvs $592.27M+80%
- P/E (TTM)24.8xvs 75.0x+67%
- ROIC (TTM)8.37%vs 5.05%+40%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.